Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 172-178

  Narimatsu, Shizuo ^a   Takemi, Chie ^a   Tsuzuki, Daisuke ^b   Kataoka, Hiroyuki ^a   Yamamoto, Shigeo ^a   Shimada, Noriaki ^a   Suzuki, Satoshi ^c   Satoh, Tetsuo ^c   Meyer, Urs A ^d   Gonzalez, Frank J ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b DAIICHI PURE CHEMICALS CO LTD   (Japan)

^c UNIVERSITY OF BASEL   (Switzerland)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1'' HYDROXYBUFURALOL; BUFURALOL; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; OMEPRAZOLE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INSECT CELL; LIVER METABOLISM; LIVER MICROSOME; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOCHEMISTRY;

ADULT; AGED; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ETHANOLAMINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYDROXYLATION; ISOENZYMES; KINETICS; MALE; MICROSOMES, LIVER; MIDDLE AGED; STEREOISOMERISM; UNITED STATES;

EID: 0036784537     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.036533     Document Type: Article

References (21)

1. Cosme J and Johnson EF (2000) Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis and membrane binding. J Biol Chem, 275:2545-2553.
2. Gonzalez FJ (1996) The CYP2D Subfamily, in "Cytochromes P450: Metabolic and Toxicological Aspects," ed. by C. Ioannides, CRC Press, Boca Raton, FL, 1996, pp. 183-210.
3. Hamilton TC and Parkes MW (1977) Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: pharmacology. Arzneim-Forsch 27:1410-1417.
4. Ko JW, Sukhova N, Thacker D, Chen P, and Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos, 25:853-862.
5. Kronbach T, Mathy D, Gut J, Catin T, and Meyer UA (1987) High-performance liquid chromatographic assays for bufuralel 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
6. Machin PJ, Hurst DN, and Osbond JM (1985) Beta-adrenoceptor activity of the stereoisomers of the bufuralol alcohol and ketone metabolites. J Med Chem 28: 1648-1651.
7. Mankowski DC (1999) The role of CYP2C19 in the metabolism of (+/-)bufuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 27:1024-1028.
8. Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
9. Meier UT, Kronbach T, and Meyer UA (1985) Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem, 151:286-291.
10. Meyer UA and Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann Rev Pharmacol Toxicol 37:268-296.
11. Narimatsu S, Gotoh M, Masubuchi Y, Horie T, Ohmori S, Kitada M, Kageyama T, Asaoka K, Yamamoto I, and Suzuki T (1996a) Stereoselectivity in bunitrolol 4-hydroxylation in liver microsomes from marmosets and Japanese monkeys. Biol Pharm Bull, 19:1429-1433.
12. Narimatsu S, Huang Y, Mizukami T, Masubuchi Y, and Suzuki T (1994) Development of a high-performance liquid chromatographic method for the analysis of enantiomer/enantiomer interaction in oxidative metabolism of bunitrolol in rat liver microsomes. Anal Biochem, 222:256-261.
13. Narimatsu S, Kato R, Horie T, Ono S, Tsutsui M, Yabusaki Y, Ohmori S, Kitada M, Ichioka T, Shimada N, Kato R, and Ishikawa T (1999) Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6. Chirality, 11:1-9.
14. Narimatsu S, Kobayashi N, Masubuchi Y, Horie T, Kakegawa T, Kobayashi H, Hardwick JP, Gonzalez FJ, Shimada N, Ohmori S, Kitada M, Asaoka K, Kataoka H, Yamamoto S and Satoh T (2000) Species difference in enantioselectivity for the oxidation of propranolol by cytochreme P450 2D enzymes. Chem-Biol Interact, 127:73-90.
15. Narimatsu S, Mizukami T, Huang Y, Masubuchi Y, and Suzuki T (1996b) In vitro interaction of bunitrolol enantiomers in rabbit liver microsomes. J Pharm Pharmacol, 48:1185-1189.
16. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos, 23:154-158.
17. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol, 3:566-573.
18. Relling MV, Aoyama T, Gonzalez FJ, and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther, 252:442-447.
19. Riley RJ, Lambert C, Cooper AE, Richmond H, Hall M, Jordan MC, Logan CJ, and Clark B (1995) Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride. Drug Metab Dispos 23:922-928.
20. Weerawarna SA, Geisshusler SM, Murthy SS, and Nelson WL (1991) Enantioselective and diastereoselective hydroxylation of bufuralol. Absolute configuration of the 7-(1-hydroxyethyl)-2-[1-hydroxy-2-(tert-butylamino)ethyl]benzofurans, the benzylic hydroxylation metabolite. J Med Chem 34:3091-3097.
21. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengericj FP, and Shimada T (1994) Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol, 46:568-577.